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Management of gestational diabetes mellitus
Abstract: The incidence of gestational diabetes mellitus (GDM) is on the increase and, if not 
diagnosed, managed and treated adequately, can have unfavorable maternal and fetal outcomes. 
Several studies have shown that glycemic values considered as adequate in the past when 
monitoring GDM failed to contain these adverse outcomes and randomized trials are needed to 
ascertain whether these targets should be lowered. Dietary restrictions remain the mainstay of 
GDM management and suitable physical exercise can help too. The use of rapid-acting insulin 
analogues (lispro and aspart) are novel treatments for improving metabolic control by reducing 
postprandial glycemia, while long-acting insulin analogues need to be evaluated by further 
studies for safety in clinical use before they can be prescribed. Numerous studies have found 
glyburide and metformin safe in women with GDM but more randomized controlled trials are 
needed, with a long-term follow-up of mother and child, to confirm these results.
Keywords: gestational diabetes, glucose management, obstetric management, maternal 
complications, fetal complications
Introduction
Gestational diabetes mellitus (GDM) is classically defined as “Carbohydrate intolerance 
resulting in hyperglycemia of variable severity with onset or first recognition during 
pregnancy”.1 It does not rule out a prior unidentified glucose intolerance, and in fact 
several studies have found 10% to 15% of cases of undiagnosed type 2 diabetes 
mellitus among GDM patients.2 The disorder affects 5% to 7% of all pregnancies and 
its frequency is rising the world over.3
Insulin resistance increases in normal pregnancy due to progressively rising levels 
of feto-placental hormones such as progesterone, cortisol, growth hormone, prolactin 
and human placental lactogen.4 The pancreas normally compensates by increasing 
insulin secretion, but when it fails to do so, or when insulin secretion declines due 
to a beta-cell function impairment,5,6 then GDM develops. Maternal hyperglycemia, 
which is typical of GDM, causes a greater transfer of glucose to the fetus, causing fetal 
hyperinsulinemia7 and an overgrowth of insulin-sensitive (mainly adipose) tissues, with 
consequent excessive, unbalanced fetal growth, causing more trauma at birth, shoulder 
dystocia and perinatal deaths. Hyperinsulinemia can also cause numerous neonatal 
metabolic complications, such as hypoglycemia, hyperbilirubinemia, hypocalcemia, 
hypomagnesemia, polycythemia, respiratory distress syndrome, and a greater long-
term risk of diabetes mellitus and obesity in the child.8,9 GDM is related to maternal 
complications too, such as hypertension, pre-eclampsia, greater need for cesarean 
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delivery,8,9 and a greater risk of developing diabetes mellitus 
later on. It is worth emphasizing that rising levels of obes-
ity worldwide have prompted an increase in the numbers 
of obese women who become pregnant, and who develop 
GDM. Pregnancy complicated by obesity is characterized by 
higher adverse maternal and fetal outcome rates, especially 
in GDM patients.10
Given the pathophysiology of GDM, most women with 
GDM subsequently develop type 2 diabetes. A systematic 
literature review found a cumulative incidence of conversion 
from GDM to type 2 diabetes that varied widely (from 
2.6% to 70%), largely due to differences in the duration of 
follow-up and cohort retention rates. After adjusting for such 
differences, a rapid rise in the cumulative incidence of type 
2 diabetes emerged in the first 5 years after delivery.11
Managing GDM: clinical evidence
The potential benefits of medical and obstetric GDM 
management are fewer maternal and fetal complications 
during and after pregnancy,12 but the clinical entity of 
GDM13 and the utility (in terms of costs and maternal and 
fetal benefits) of screening for GDM have recently been 
questioned.14,15 Since it is sometimes difficult to distin-
guish GDM from prior undiagnosed type 2 diabetes, it is 
also not easy to assess the risks and benefits of treating 
GDM. In a recent review on the treatment of GDM and 
glucose intolerance in pregnancy, Tufnell et al14 concluded 
that there are insufficient data for any conclusion on the 
effects of treatment for these conditions on perinatal out-
come. A systematic review for the US Preventive Serv-
ices Task Force said that, “limited evidence suggests that 
GDM treatment after 24 weeks improves some maternal 
and neonatal outcomes. Evidence is even more sparse for 
screening before 24 weeks of gestation.”15
On the other hand, Langer et al16 recently recorded 
composite adverse fetal outcomes (stillbirth, macrosomia, 
large for gestational age, hypoglycemia, erythrocytosis, 
hyperbilirubinemia) in 59% of untreated and 18% of treated 
GDM women, and in 11% of normal controls. The Australian 
Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS)17 unequivocally demonstrated that treating GDM 
(as defined by World Health Organization [WHO] criteria) 
improves maternal and fetal outcome. The rate of severe 
perinatal outcomes in newborn was significantly lower 
in the treated group than in the control group (1% vs 4%, 
p = 0.01), and quality of life was improved in the treated 
group. Cost analysis showed that the treatment was cost-
effective.18 Finally, a cost-effectiveness study by the National 
Institute for Clinical Excellence (NICE) demonstrated that 
GDM screening, diagnosis and treatment is cost-effective, 
irrespective of the type of pharmacological treatment used.19 
Hence, even if some controversy remains, GDM is a genuine 
clinical entity that warrants diagnosis and treatment.20
Glucose management (Table 1)
The goal of glucose management in GDM is to keep glucose 
values as near normal as possible.
The Fifth International Workshop Conference (FIWC) on 
GDM21 suggests capillary whole blood glucose concentrations 
below 96 mg/dL (5.3 mmol/L) before meals and either below 
140 mg/dL (7.8 mmol/L) 1 h afterwards or below 120 mg/dL 
(6.7 mmol/L) 2 h afterwards. The reference plasma glucose 
levels suggested by the American Diabetes Association 
(ADA) are below 105 mg/dL (5.8 mmol/L) before meals 
and either below 155 mg/dL (8.6 mmol/L) 1 h afterwards, or 
below 130 mg/dL (7.2 mmol/L) 2 h afterwards.3
It is worth emphasizing, however, that these recommen-
dations do not consider glycemic values higher than those 
normally recorded in pregnancy, they refer to glycemic 
levels associated with pregnancy outcome.22 This is mainly 
because studies on glycemia in normal pregnant women 
are scarce, concern few hospitalized women and glucose 
levels were measured only on one day in the third trimester 
of pregnancy.23–25
In a more recent study on normal-weight pregnant women 
monitoring their own blood glucose levels, Parretti et al26 
Table 1 Glycemic target in pregnancy
ADA3 
4th IWC 199822
ACOG 200152 Parretti 200126 
SBGM
Yogev 2003 27 
CGMS
Siegmund 
200728 CGMS
FPG (mg/dL) 95 60–90 62 ± 4.5 75 ± 12 77.3 ± 9.0
1 h PPPG (mg/dL) 140 130–140 94 ± 6 105 ± 13 100.0 ± 12.6
2 h PPPG (mg/dL) 120 120 81.4 ± 5.7 97 ± 11 –
Mean blood glucose (mg/dL) – 100 74.7 ± 5.2 83.7 ± 18 87.2 ± 7.2
Abbreviations: FPG, fasting plasma glucose; 1 hPPPG, 1 hour postprandial plasma glucose; 2 hPPPG, 2 hour postprandial plasma glucose; SBGM, self blood glucose monitoring; 
CGMS, continuous glucose monitoring system.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 75
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found lower glycemic levels than those previously reported, 
both before and after meals, which gradually increased from 
the 28th to the 38th week of gestation.
Nowadays, continuous glucose monitoring systems 
(CGMS) use subcutaneous sensors impregnated with glucose 
oxidase to assess subcutaneous interstitial glucose levels every 
10 seconds. These devices have added to our understanding of 
normal glucose values in pregnancy. This approach revealed 
that in normal pregnant women27,28 glucose levels were simi-
lar to those found by Parretti et al26 with significantly lower 
levels at night than during the day.27 The same authors27 also 
showed that obese pregnant women have significantly lower 
blood glucose levels at night. Langer et al subsequently found 
that maintaining a good glycemic control in obese women 
(mean plasma glucose 100 mg/dL) is only associated with 
a favorable fetal outcome in women treated with insulin.29 
This might mean that different glycemic values are needed in 
obese GDM women to reduce fetal and maternal complica-
tions, though prospective studies are needed to clarify this 
issue before current recommendations can be changed.
Measuring glucose levels after meals is more important 
than pre-prandial levels in GDM patients because it 
correlates better with certain adverse neonatal events, eg, 
malformations, macrosomia, hypoglycemia, and shoulder 
dystocia.30,31
There is some debate as to whether glucose should be 
measured 1 or 2 hours after a meal. Continuous blood glucose 
monitoring has recently shown that glucose peaks occur about 
70 ± 13 min after meals in non-diabetic pregnant women27 
and after about 90 min in diabetic women, whatever their 
glycemic control and type of treatment.32 No differences in 
postprandial glycemic profile emerged between breakfast, 
lunch and dinner. A recent review showed that patients 
managed according to the glucose levels measured an hour 
after meals, generally had babies with a lower birth weight, 
less neonatal hypoglycemia, less macrosomia and fewer 
cesarean deliveries than patients whose glucose levels were 
tested 2 hours after meals.33
As for glycemic levels and neonatal complications of 
GDM, Langer et al34,35 found higher macrosomia rates with 
mean blood glucose levels higher than 105 mg/dL, whereas 
the risk of babies being small for their gestational age was 
high when the mean blood glucose levels dropped below 
87 mg/dL; mean blood glucose values should therefore be 
kept between 87 mg/dL and 105 mg/dL in GDM patients to 
avoid these fetal complications.21
As for fetal deaths, Pettitt et al36 reported a higher risk 
of stillbirth related mainly to excessive fetal growth, and 
Bartha et al37 found that stillbirths were more common 
among women whose GDM was diagnosed early than 
in those diagnosed later in their pregnancy; Aberg et al 
confirmed these data.38 Beischer et al39 also documented a 
higher perinatal mortality rate in untreated than in treated 
GDM patients. The increase in fetal death rates thus depends 
on the severity of glucose intolerance and the degree of 
glycemic control. The ADA’s position statement3 suggests 
that fasting blood glucose levels higher than 105 mg/dL 
carries a greater risk of perinatal mortality in GDM patients. 
Karlson and Kielmer40 also found an association between 
mean blood glucose levels and perinatal mortality, which 
was 4% in GDM women with mean plasma glucose levels 
below 100 mg/dL, 15% if it was 100 mg/dL to150 mg/dL, 
and 24% if it exceeded 150 mg/dL.
As for glycemic control and the other GDM-related 
fetal complications (hypoglycemia, hypocalcemia, 
hyperbilirubinemia and respiratory complications), Langer 
et al postulated earlier that mean blood glucose levels 
below 100 mg/dL (as in normal pregnant women) reduce 
the incidence of all these complications.41,42 A more recent 
paper16 clearly showed that maternal and fetal complication 
rates were still higher in GDM than in normal pregnant 
women, even when strictly treated to achieve the above-
mentioned plasma glucose levels.
The thresholds used in the past to prevent maternal 
and fetal complications of GDM may need to be recon-
sidered in the light of recent findings in normal pregnant 
women monitoring their own blood glucose levels26 or 
using a CGMS,27,28 and of the results of the Hyperglycemia 
and Adverse Pregnancy Outcome (HAPO) study.43 This 
multicenter, blinded study addressed the risk of adverse 
outcomes associated with various degrees of maternal 
glucose intolerance less severe than overt diabetes, showing 
an association between increasing levels of fasting, 1-hour, 
and 2-hour postprandial plasma glucose (on oral glucose 
tolerance testing) and birth weight above the 90th percentile 
and cord C-peptide above the 90th percentile, as well as a 
positive association between rising plasma glucose levels 
and each of five secondary outcomes examined (premature 
delivery, shoulder dystocia or birth injury, admission 
to the neonatal intensive care, hyperbilirubinemia and 
preeclampsia).
Achieving a good glycemic control is therefore very 
important to reduce fetal complications in GDM and it is 
worth emphasizing that a good glucose control needs to be 
achieved without any hypoglycemic episodes, since CGMS 
has shown that women with GDM may have hypoglycemic Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 76
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episodes too (contrary to common convictions), especially 
if they are treated with insulin, and such episodes are 
generally asymptomatic.44 Finally, we have to consider the 
daily fluctuations in glycemia, which may contribute to cer-
tain neonatal complications, as demonstrated recently.45,46 
Taslimi et al found that the glycemia index correlated better 
with birth weight percentile than blood glucose monitored 
by conventional methods in pregnant women with type 1 
diabetes and GDM.46
Glycemic control can also be evaluated by measuring 
HbA1c. Although standardized measurements have shown that 
HbA1c levels are significantly higher in GDM patients than 
in normal pregnant women,47 the association between HbA1c 
levels and pregnancy outcome in these patients is weak.48,49 
When considering HbA1c levels in diabetic pregnant patients, 
we must refer to the values for normal pregnant women 
(which are lower than in women who are not pregnant)47,50 and 
standardized methods are needed to obtain valid results.51
Obstetric management
Obstetric management is just as essential as metabolic 
management, and fetal monitoring is very important to decide 
the best time and mode of delivery.
Insulin-treated GDM patients and those with a poor 
metabolic control and/or comorbidities need to be 
monitored using “stress-free tests” in the 32nd week of 
gestation, and umbilical blood flow should be assessed 
using a biophysical profile and Doppler velocimetry as 
recommended by the Fourth IWC on GDM,22 the American 
College of Obstetricians and Gynecologists (ACOG),52 and 
the European Association of Perinatal Medicine (EAPM).53 
In GDM patients on a controlled diet, it is not clear whether 
strict obstetric management should entail anything more 
than monitoring fetal movements in the last 8 to10 weeks 
of pregnancy. Garner et al54 recorded no stillbirths among 
GDM women under routine obstetric management with 
no predelivery fetal monitoring. According to the ACOG52 
and the FIWC on GDM,21 fetal movement should be 
monitored during the last 8 to10 weeks of pregnancy in 
GDM patients with good metabolic control achieved by 
dietary measures and with an appropriate fetal growth. 
Any decline in the perceived fetal movements should be 
reported immediately to the obstetrician. The results of a 
large randomized multicenter study that compared perinatal 
outcome between women with mild GDM randomized to 
dietary and/or insulin therapy and women randomized to 
nonspecific treatment should clarify the optimal strategy 
for managing GDM.55
Screening for congenital anomalies is only recommended 
in GDM patients with HbA1c levels higher than 7% or fasting 
plasma glucose levels higher than 120 mg/dL, given the high 
risk of undiagnosed prepregnancy diabetes and the conse-
quently high risk of congenital malformations.21
An important point to consider when monitoring GDM 
is the chance to predict and treat macrosomia, the most 
common complication of this condition. In order to plan 
any treatment designed to contain excess fetal growth, we 
need to know when this phenomenon sets in. An ultrasound 
(US) study on fetal lean and fat mass in GDM and normal 
pregnant women at various gestational ages showed that lean 
mass increases in the GDM fetus from the 20th gestational 
week (g.w) onwards and fat mass from the 26th g.w.56 The 
accuracy of US estimates of fetal weight is commonly 
expressed as sensitivity, specificity, positive and negative 
predictive values, and proportions of estimates within 10% 
of actual birth weight.57,58 The mean absolute error in the 
birth weight predicted using US is in the range of 6% to 12% 
of the actual birth weight, with 40% to 75% of estimates 
coming within 10% of the actual birth weight.59 However, 
US fetal measurements have proved to depend on the exam-
iner’s expertise.60 Moreover, studies comparing clinical and 
US measurements found neither method superior, US proving 
more accurate only in the low birth weight range.61 A recent 
study also showed that the positive predictive value of US in 
assessing birth weights above the 95th percentile in women 
with varying degrees of glucose intolerance is only 50%.62 
In another recent study, Pates et al63 found that US estimates 
of fetal weight of 4000 g or more, based on fetal abdominal 
circumference, biparietal diameter, head circumference and 
femur length, within a week of delivery and a higher than 
normal amniotic fluid index in combination with clinical 
risk factors (maternal parity, BMI and diabetes) improved 
the prediction of macrosomia from 61% to 71%.
Newly-developed technologies, such as 3D US and 
magnetic resonance imaging, are promising in this setting, 
having proved highly accurate in measuring fetal weight from 
a volumetric assessment of the fetus.64,65 Most such studies 
published to date refer to only a few cases, however, and the 
cost-benefit ratio of these technologies needs to be determined 
before it can be considered routinely applicable.66
There is evidence from some studies that a fetal abdominal 
circumference beyond the 75th percentile and fasting plasma 
glucose levels beyond 105 mg/dL correlate with a high risk of 
the newborn being large for gestational age (LGA); in such 
cases, stricter glycemic targets (80 mg/dL while fasting and 
100 mg/dL to120 mg/dL, 2 h after meals) and a more frequent Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 77
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use of insulin for treatment may reduce the number of babies 
that are LGA by 50%.67,68 Hence the recommendation from 
FIWC on GDM21 that fetal abdominal circumference be 
assessed every 2 to 4 weeks, from the second trimester to 
provide useful indicators for the treatment of GDM.
Given the contribution of fat mass to fetal weight, 
measuring soft tissue thickness might seem more accurate 
than whole body (fat and lean tissue) measurements.69 This 
method is highly sensitive, but scarcely specific; whereas 
measuring subcutaneous fetal fat tissue has proved to be 
both sensitive and specific.70,71 Such methods have yet to 
become routine in monitoring GDM patients, and further 
studies are needed to establish their real utility and cost-
benefit ratio.66
Diet
The goals of medical therapy in GDM patients are to establish 
the right diet in terms of quality and quantity of nutrients to 
ensure normal maternal weight gain and fetal growth, optimize 
glycemic control, avoid ketoacidosis and reduce glucose 
levels after meals, since adverse maternal and fetal outcomes 
have been associated with hyperglycemia after meals. To 
achieve these goals, it is important for GDM patients to 
be followed-up by a team and included in an educational 
program, customize weight gain and calorie intake, and 
establish their needs in terms of type and distribution of 
carbohydrates, optimal protein, fat and micronutrient intake, 
and amount and type of physical activity.72
Maternal weight gain during pregnancy and BMI before 
pregnancy affect the infant’s birth weight. Taking the original 
recommendation on Nutrition for Pregnancy of the Institute 
of Medicine (IOM) into account,73 the Fourth IWC on GDM,22 
and the EAPM Guidelines53 recommend a weight gain of 
12.7 kg to 18.2 kg for pregnant women with a prepregnancy 
BMI lower than 19.8; 11.4 kg to 15.9 kg for pregnant women 
with a prepregnancy BMI between 19.8 and 26; 6.8 kg to 
11.4 kg for pregnant women with a prepregnancy BMI 
between 26.1 and 29; and 6.8 kg for pregnant women with 
a prepregnancy BMI higher than 29. The ideal calorie intake 
in GDM patients is a debatable point; while it is generally 
agreed that underweight and normal-weight GDM patients 
should have the calorie intake recommended by the IOM,73 
there is no such consensus for overweight and obese GDM 
patients and some authors advocate severe calorie restriction 
in such cases.74,75 Studies by Knoop et al74 and Magee 
et al75 using severe calorie restriction (1,200 kcal/day or 
a 50% reduction in daily kcal intake) have clearly shown, 
however, that even if this approach can improve glycemia, 
it also increases ketonuria, which has been associated with 
an altered mental development in children born to GDM 
mothers.76 Conversely, a more modest calorie restriction 
(1,600–1,880 kcal/day or a 33% reduction in daily kcal 
intake) improved glycemia and triglyceride levels without 
causing ketonuria.77,78
So, in accordance with the ADA,3 we suggest a daily 
calorie intake and distribution as shown in Table 2.
As for the optimal carbohydrate intake, since carbohydrates 
are a fundamental dietary resource for fetal brain development 
and at least 130 g/day of carbohydrates are needed in the 
normal population, pregnant women need about 33 g more, 
ie, 175 g of carbohydrates a day.73
It has recently been demonstrated that foods with a low 
glycemic index induce smaller increases in postprandial 
glucose levels and this might be important in GDM women, 
whose glucose levels are often high after meals.79,80 So, even 
if no randomized trials have been conducted as yet to test a 
Table 2 Calorie intake and distribution in GDM women
Calorie intake in accordance with BMI 
(kcal/kg actual weight)
Caloric distribution
•  19.8    36–40 •  Breakfast 10%–15%
•  19.8–26     30 •  Snack 5%–10%
•  26.1–33     24 •  Lunch 20%–30%
•  33      12–18 •  Snack 5%–10%
+340–452 kcal/die in 2nd and 3rd trimester •  Dinner 30%–40%
• Snack 5%–10% (25 g CHO + 10 g P)
Nutrient distribution
CHO 45%–50% (complex carbohydrate and fiber)
P 15%–20%
L 30%–35% (mono and polyunsaturated)
Abbreviations: CHO, carbohydrates; P, proteins; L, lipids.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 78
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carbohydrate-rich diet with a low glycemic index in GDM 
patients, we would recommend using such a diet, suitably 
tailored to individual patients, in cases of GDM.
As for the other nutrients, vitamins and minerals, GDM 
women need to follow the same guidelines as normal 
pregnant women.
Exercise in GDM
It is well known that physical activity reduces glucose and 
insulin resistance in diabetic patients thereby helping them 
to control their weight, so it may be useful as adjunctive 
therapy in GDM women too.
The ADA suggests that women without medical or 
obstetric contraindications should be encouraged to start 
or continue a program of moderate exercise as part of their 
treatment for GDM.3 The Fourth IWC statement on GDM 
says that, “a planned physical activity of 30 min/day is 
recommended.”22 However, when exercise was studied in 
terms of its capacity to reduce plasma glucose and delay 
or prevent the need for insulin therapy, the results were 
inconclusive (due probably to the small samples considered, 
the lack of any randomization of the subjects, and the poor 
control or inadequate reporting of the intensity of the exercise 
concerned). The Cochrane study concluded that there is 
insufficient evidence to either recommend or advise against 
enrolling GDM patients in exercise programs,81 although 
several epidemiological studies have shown a link between 
physical activity and a lower risk of GDM.82,83
Here again, further studies are needed to determine the 
optimal frequency, intensity, timing and type of exercise to 
recommend in GDM patients. Given the potential benefits 
of exercise in GDM, for uncomplicated pregnancies we can 
follow the recommendations of the Fourth IWC on GDM22 
and the ACOG,52 provided GDM women monitor their blood 
glucose levels and fetal activity before and after exercising 
(Table 3).
Insulin therapy
Insulin is needed when dietary restrictions fail to achieve 
near-normal glucose control in GDM women. How long 
dietary measures alone should be attempted before starting 
insulin therapy depends on the patient’s glycemic control and 
the baby’s gestational age when GDM is diagnosed. It takes 
two weeks before one can say whether dietary measures alone 
suffices. Insulin dosage is calculated on a patient’s weight and 
it is best to start with 0.7 U/kg in normal-weight patients and 
0.8–1.0 U/kg in the obese.84 Basal insulin is administered at 
bedtime, or both before breakfast and at bedtime; rapid-acting 
insulin (regular, lispro, aspart) is taken before meals.
Since improving postprandial hyperglycemia can reduce 
some negative maternal and fetal outcomes, the new insulin 
analogues may be beneficial in GDM patients.85,86 Regarding 
their safety, the first question is whether they cross the 
placenta and have harmful effects on the fetus; the second 
is whether they are really effective.
Animal studies found no embryotoxic or teratogenic 
effects of insulin lispro, and clinical and in vitro perfusion 
studies have shown that insulin lispro does not cross the 
placenta at the doses currently used in pregnancy.87 In 
GDM patients, insulin lispro has been associated with the 
formation of antibody resembling regular insulin and with 
lower levels of glucose, insulin and C-peptide after meals, 
and fewer hypoglycemic episodes than in patients on regular 
insulin.88
As for insulin aspart, animal studies have again identified 
no embryotoxic or teratogenic effects, while no studies have 
Table 3 Guidelines of the ACOG for exercise during pregnancy
Exercise recommended in pregnancy Exercise to be avoided in pregnancy
1. walking 1. skiing
2. jogging/running 2. horseback riding
3. aerobic dance 3. ice hockey
4. swimming 4. soccer
5. cycling 5. basketball
6. dancing 6. scuba diving
Intensity of exercise
•  60%–90% of maximal heart rate
•  50%–85% of either maximal oxygen uptake or heart rate reserve
Duration and frequency
•  30 minutes a day (in absence of either medical or obstetric complications)Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 79
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been performed so far on its ability to cross the placenta. In 
GDM, using aspart has proved more effective than regular 
insulin in reducing postprandial glucose and C-peptide 
concentrations.89
No data are currently available on the use of glulysine 
in pregnancy.
Regarding long-acting insulin analogues, animal 
studies on insulin glargine have disclosed no embryotoxic 
or teratogenic effects, while some toxic effects (early 
intrauterine death, congenital malformations) correlated with 
the hypoglycemia induced by high doses of insulin.90 No data 
are available as yet on the capacity of these insulin analogues 
to cross the placenta. In a case-control pilot study involving 
22 GDM cases treated with insulin glargine, Price et al could 
find no differences in maternal and fetal outcomes.91
We still have no data on the use of insulin detemir in 
pregnancy.
Based on these studies, insulin lispro and aspart appear 
to be just as safe and effective as regular insulin in GDM, 
while achieving a better postprandial glucose concentration 
and fewer hypoglycemic episodes. The safety of the new 
long-acting insulin analogues in pregnancy needs to be 
further analyzed, so they are not currently recommended in 
diabetic pregnant women.
Oral hypoglycemic drugs
These drugs are generally not prescribed during pregnancy 
because they are believed to cross the placenta and might 
cause fetal/neonatal hyperinsulinemia and hypoglycemia. 
There is also concern as to their teratogenicity when used 
in the first trimester of pregnancy. For hypoglycemic drugs, 
we still need to answer the same questions as for the new 
insulin analogues.
Glyburide has revealed only a minimal placental transfer92 
and several studies (involving almost 1261 GDM cases) 
showed adequate glycemic control in most patients, fewer 
hypoglycemic episodes than with insulin treatment, and 
neonatal outcomes similar to those achieved with insulin.93,94 
On the other hand, a recent study on 500 GDM women 
reported a significantly higher frequency of preeclampsia and 
the need for phototherapy in glyburide-treated patients.95
Given the above, this drug might be prescribed in GDM 
patients if maternal glycemic control and fetal development 
are monitored closely.
Metformin has been shown to cross the placenta, with 
fetal levels becoming about half those of the mother.96
The recent randomized Metformin and Gestational 
Diabetes (MIG) trial assessing the safety and efficacy of 
metformin in 363 GDM women showed that metformin, 
alone or with insulin supplementation, was not associated 
with more perinatal complications than insulin alone, but 
insulin had to be associated with the metformin in 46% of 
cases to achieve an adequate metabolic control.97
Metformin has been associated with fewer cases of GDM 
among women with polycystic ovary syndrome,98 and it 
was responsible for no neonatal complications in terms of 
malformations, birth weight or neonatal hypoglycemia.99
Because it crosses the placenta and relatively few cases 
have been treated so far, it would be prudent to await more 
information before assuming it is safe to use this drug in 
pregnancy.
Acarbose might be used if the patient tolerates the related 
gastrointestinal discomfort; a randomized trial on this drug 
is underway and the results will tell us more about its safety 
profile.100
Thiazolinediones101 cross the placenta and, apart from 
one or two case studies, we know nothing about its safety 
in pregnancy. The same goes for incretin mimetics, which 
should not be used in pregnancy for the time being.102
Conclusions
The incidence of GDM is increasing and, if not diagnosed, 
managed and treated adequately (Figure 1), can have 
unfavorable maternal and fetal outcomes. Several studies 
have shown that the glycemic values considered adequate 
in the past when monitoring GDM were unable to contain 
these adverse outcomes and randomized trials are needed 
to ascertain whether these targets should be lowered. 
New methods for assessing glycemic control and fetal 
GDM diagnosis
Diet and physical exercise
Glucose monitoring
FPG < 95 mg/dL
2 h PPG < 120 mg/dL
MPG < 96 mg/dL
FPG > 95 mg/dL and / or
2 h PPG > 120 mg/dL
Diet Insulin therapy
Figure 1 Management of gestational diabetes.
Abbreviations: FPG, fasting plasma glucose; 2 h PP, 2 h postprandial glucose; MPG, 
mean plasma glucose.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 80
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development seem promising, but have to be tested for 
routine use. Dietary restrictions remain the mainstay of 
GDM management, and suitable physical exercise can help 
too. Rapid-acting insulin analogues (lispro and aspart) are 
novel treatments for improving metabolic control by reducing 
postprandial glycemia, while long-acting insulin analogues 
need further study on the related safety issues before they can 
be prescribed. Numerous studies have found glyburide and 
metformin safe in GDM pregnancies, but more randomized 
controlled trials are needed in type 2 diabetic and GDM 
women, with a long-term follow-up of mother and child, to 
confirm these results.
Disclosures
The authors disclose no conflicts of interest.
References
  1.  Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus. Report of the Expert committee on the diagnosis and 
classification of diabetes mellitus. Diabetes Care. 1997;20:1183–1197.
  2.  Langer O. Type 2 diabetes in pregnancy: exposing deceptive 
appearances. J Matern Fetal Neonatal Med. 2008;21(3): 181–189.
  3.  American Diabetes Association. Gestational Diabetes Mellitus (Position 
Statement). Diabetes Care. 2004;27(Suppl 1):S88–S90.
  4.  Ryan EA, Enns L. Role of gestational hormones in the induction of 
insulin resistance. J Clin Endocrinol Metab. 1988;67:341–347.
  5.  Kuhl C. Etiology and pathogenesis of gestational diabetes. Diabetes 
Care. 1998;21:B19–B26.
  6.  Lapolla A, Dalfrà MG, Mello G, et al. Early detection of insulin 
sensitivity and beta cell function with simple tests indicate 
future derangements in late pregnancy. J Clin Endocrinol Metab. 
2008;93(3):876–880.
  7.  Pedersen J. The Pregnant Diabetic and her Newborn. 2nd ed. Munksgaard: 
Copenhagen and Williams and Wilkins: Baltimore; 1977:211.
  8.  Casey BM, Lucas MJ, McIntire DD, Leveno KJ. Pregnancy outcomes 
in women with gestational diabetes compared with the general obstetric 
population. Obstet Gynaecol. 1997;90:869–873.
  9.  Kjos AL, Buchanan TA. Gestational diabetes mellitus. N Engl J Med. 
1999;341:1749–1756.
10.  Langer O. Management of obesity in GDM:old habits die hard. J Matern 
Fetal Neonatal Med. 2008:21(3):165–171.
11.  Kim C, Newton KM, Knoop RH. Gestational diabetes and the incidence 
of type 2 diabetes. Diabetes Care. 2002;25:1862–1868.
12.  Scott DA, Loveman E, McIntire L, Waugh N. Screening for gestational 
diabetes: a systematic review and economic evaluation. Health Technol 
Assess. 2002;6(11):1–172.
13.  Hunter DJS, Milner R. Gestational diabetes and birth trauma. Am J 
Obstet Gynecol. 1985:152:918–919.
14.  Tuffnell DJ, West J, Walkinshaw SA. Treatments for gestational 
diabetes and impaired glucose tolerance in pregnancy. The Cochrane 
Library 2008;(4):1–30.
15.  Hiller TA, Vesco KK, Pedula KL, Beil TL, Whitlock EP, Pettitt DJ. 
Screening for gestational diabetes mellitus: a systematic review for the US 
Preventive Service Task Force. Ann Intern Med. 2008;148:766–775.
16.  Langer O, Yogev Y, Most O, Xenachis EM. Gestational diabetes: the 
consequences of not treating. Am J Obstet Gynaecol. 2005;192:989–997.
17.  Crowther CA, Hiller JE, Moss AJ, Jeffries WS, Robinson JS; for 
the Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS) Trial Group. Effect of treatment of gestational diabetes 
mellitus on pregnancy outcomes. New Engl J Med. 2005;352(24): 
2477–2486.
18.  Moss JR, Crowther CA, Hiller JE, Willson KJ, Robinson JS; for 
the Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS) Trial Group. Costs and consequences of treatment for mild 
gestational diabetes mellitus-evaluation from the ACHOIS randomised 
trial.BMC Pregnancy Childbirth. 2007;7:27–33.
19.  National Institute for Health and Clinical Excellence. Cost-effectiveness 
of screening, diagnosis and treatment for gestational diabetes. March 
2008; Appendix D:165–190.
20.  Langer O. Gestational diabetes: the consequences of not treating. 
In: M Hod, L Jovanovic, GC Di Renzo, A DeLeiva, O Langer, eds. 
Textbook of Diabetes and Pregnancy. 2nd ed. Informa Healthcare; 
2008;107–117.
21.  Metzer BE; Buchanan TA, Coustan DR, et al. Summary and 
Recommendations of the Fifth International Workshop-Conference on 
Gestational Diabetes Mellitus. Diabetes Care. 2007;30(2): S251–S260.
22.  Metzger BE, Coustan DM. Organizing Committee: Summary and 
Recommendations of the Fourth International Workshop Conference 
on Gestational Diabetes Mellitus. Diabetes Care. 1998;21 (Suppl 2):
B161–167.
23.  Gilmer MD, Beard RW, Brooke FM, Oakley NW. Carbohydrate 
metabolism in pregnancy. Part 1: diurnal plasma glucose profile in 
normal and diabetic women. Br Med J. 1975;3:399–402.
24.  Cousins L, Rigg L, Hollingsworth D, Brink G, Aurand J, Yen SS. The 
24-hour excursion and diurnal rhythm glucose, insulin and C-peptide 
in normal pregnancy. Am J Obstet Gynecol.1980;136:483–488.
25.  Phelps RL, Metger BE, Freinkel N. Carbohydrate metabolism in 
pregnancy. XVII. Diurnal profiles of plasma glucose, insulin, free 
fatty acids, triglycerides, cholesterol, and individual amino acids in 
late normal pregnancy. Am J Obstet Gynecol. 1981;140:730–736.
26.  Parretti E, Mecacci F, Papini M, et al. Third trimester maternal glucose 
levels from diurnal profiles in non diabetic pregnancies: correlation 
with sonographic parameters of foetal growth. Diabetes Care. 
2001;24:1319–1323.
27.  Yogev Y, Ben-Haroush A, Chen R, Rosenn B, Hod M, Langer O. Diurnal 
glycemic profile in obese and normal weight non diabetic pregnant 
women. Am J Obstet Gynecol. 2004;191:949–953.
28.  Siegmund T, Rad NT, Ritterath C, Siebert G, Henrich W, Buhling KJ. 
Longitudinal changes in the continuous glucose profile measured by 
the CGMSR in healthy pregnant women and determination of cut-off 
values. E J Obstet Gynaecol Reprod Biol. 2008;139:46–52.
29.  Langer O, Yogev Y, Xenakis EMJ, Brustman L. Overweight and obese 
in gestational diabetes: the impact on pregnancy outcome. AM J Obstet 
Gynaecol. 2005;192:1768–1776.
30.  Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal 
postprandial glucose levels and infant birth weight: Diabetes in Early 
Pregnancy Study: The National Institute of Child Health and Human 
Development –Diabetes in Early Pregnancy Study. Am J Obstet 
Gynecol. 1991;164:103–111.
31.  De Veciana M, Major CA, Morgan MA, et al. Post prandial versus pre 
prandial blood glucose monitoring in women with gestational diabetes 
mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–1241.
32.  Ben-Haroush A, Yogev Y, Chen R, Rosen B, Hod M, Langer O. The 
postprandial glucose profile in the diabetic pregnancies. Am J Obstet 
Gynecol. 2004;191:576–581.
33.  Leguizamon G, Krupitzki H, Glujovsky D, Olivera Ravasi M, Reece EA. 
Blood glucose monitoring in gestational diabetes mellitus:1-versus 
2-h blood glucose determinations. J Matern Fetal Neonatal Med. 
2002;12:384–388.
34.  Langer O, Mazze R. The relationship between large for gestational 
age infants and glycemic control in women with gestational diabetes. 
Am J Obstet Gynecol. 1988;159:1478–1483.
35.  Langer O. Prevention of macrosomia. Baillieres Clin Obstet Gynaecol. 
1991;5:333–347.
36.  Pettitt DJ, Knowless WC, Baird HR, Bennett PH. Gestational diabetes: 
infant and maternal complications of pregnancy in relation to third 
trimester glucose tolerance in Pima Indians. Diabetes Care. 1980;3: 
458–464.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 81
Managing GDM Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
37.  Bartha JL, Martinez-Del-Fresno P, Comino-Delgado R. Gestational 
diabetes mellitus diagnosed during early pregnancy. Am J Obstet 
Gynaecol. 2000;182:346–350.
38.  Aberg A, Rydhstrom H, Kallen B, Kallen K.Impaired glucose tolerance 
during pregnancy is associated with increased fetal mortality in preced-
ing sibs. Acta Obstet Gynecol Scand 1997;76:212–217.
39.  Beischer NA, Wein P, Sheedy MT, Steffen B. Identification and 
treatment of women with hyperglycemia diagnosed during pregnancy 
can significantly reduce perinatal mortality rates. Aust N Z J Obstet 
Gynaecol. 1996;182:239–247.
40.  Karlson K, Kjellmer I. The outcome of diabetic pregnancies in relation 
to the mother’s blood sugar level. Am J Obstet Gynaecol. 1972;112: 
213–220.
41.  Langer O, Rodriguez DA, Xenachis EMJ, McFarland MB, Berkus 
MD, Arrendono MD. Intensified versus conventional manage-
ment of gestational diabetes. Am J Obstet Gynaecol. 1994;170: 
1036–1047.
42.  Langer O. A spectrum of glucose thresholds may effectively prevent 
complications in the pregnant diabetic patients. Semin Perinatol. 
2002;26:196–205.
43.  The HAPO Study Cooperative Research Group. Hyperglycemia 
and adverse pregnancy outcome. N Engl J Med. 2008;358(19): 
1991–2002.
44.  Chen R, Yogev Y, Ben-Haroush A, Jovanovic L, Hod M, Philip M. 
Continuous glucose monitoring for the evaluation and improved 
control of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 
2003;14:256–260.
45.  Kerssen A, deValk HW, Visser GHA. Day-to-day glucose variability 
during pregnancy in women with type 1 diabetes mellitus: glucose 
profiles measured with the continuous glucose monitoring. BJOG. 
2004;11:919–924.
46.  Taslimi MM, Navabi K, Acosta R, Helmer A, El-Sayed YY. Concealed 
maternal blood glucose excursions correlate with birth weight centile. 
J Diab Science Technol. 2008;2(3):456–460.
47.  Mosca A, Paleari R, Dalfrà MG, et al. Reference intervals for 
haemoglobin A1c in pregnant women: data from an Italian Multicentric 
study. Clin Chem. 2006;52:1138–1143.
48.  Wyse LJ, Jones M, Mandel F. Relationship of glycosylated hemoglobin, 
fetal macrosomia and birthweight macrosomia. Am J Perinatol. 
1994;11:260–262.
49.  Weissmann-Brenner A, O’Reilly-Green C, Ferber A, Divon MY. Does 
the availability of maternal HbA1c results improve the accuracy of 
sonographic diagnosis of macrosomia? Ultrasound Obstet Gynaecol. 
2004;23:466–471.
50.  Nielsen LR, Ekbom P, Damm P, et al. HbA1c levels are significantly 
lower in early and late pregnancy. Diabetes Care. 2004;5:1200–1201.
51.  Marshall SM, Barth JH. Standardization of HbA1c measurements: a 
consensus statement. Diabet Med. 2000;17:5–6.
52.  ACOG Practice Bulletin Clinical Management Guidelines for 
Obstetrician-Gynaecologists. No 30. Obstet Gynaecol. 2001:98(3): 
525–538.
53.  European Association of Perinatal Medicine (EAPM). Diabetes and 
pregnancy update and guidelines. Hod M, Carrapato M, Eds, 2000.
54.  Garner P, Okun N, Keely E, et al. A randomised controlled trial of 
strict glycemic control and tertiary level obstetric care versus routine 
obstetric care in the management of gestational diabetes: a pilot study. 
Am J Obstet Gynaecol. 1997;177:190–195.
55.  Landon MB, Thom E, Spong CY, et al. The National Institute of 
Child Health and Human Development Maternal-Fetal Medicine 
Units Network randomized clinical trial in progress. Diabetes Care. 
2007;30(Suppl 2):S194–S199.
56.  Larciprete G, Valensise H, Vasapollo B, et al. Fetal subcutaneous tissue 
thickness (SCTT) in healthy and gestational diabetic pregnancies. 
Ultrasound Obstet Gynecol. 2003;22:591–597.
57.  Ben-Haroush A, Yogev Y, Hod M. Fetal weight estimation in 
diabetic pregnancies and suspected fetal macrosomia. J Perinat Med. 
2004;32:113–121.
58.  Colman A, Maharaj D, Hutton J, Tuohy J. Reliability of ultrasound 
estimation of fetal weight in term singleton pregnancies. NZ Med J. 
2006;119:U2146.
59.  Benacerraf BR, Gelman R, Frigoletto FD. Sonographically estimated 
fetal weights: accuracy and limitation. Am J Obstet Gynecol. 
1988;159:1118–1121.
60.  Predanic M, Cho A, Ingrid F, Pellettieri J. Ultrasonographic estimation 
of fetal weight. J Ultrasound Med. 2002;21:495–500.
61.  Sherman DJ, Arieli S, Tovbin J, Siegel G, Caspi E, Bukovsky I. 
A comparison of clinical and ultrasonic estimation of fetal weight. 
Obstetrics and Gynecology. 1998;91(2):212–217.
62.  Kernaghan D, Ola B, Fraser RB, Farrell T, Owen P. Fetal size and 
growth velocity in the prediction of the large for gestational age (LGA) 
infant in a glucose impaired population. Eur J Obstet Gynecol Reprod 
Biol. 2007 Jun; 132(2):189–192. Epub 2006 Aug 22.
63.  Pates JA, McIntire DD, Casey BM, Leveno KJ. Predicting macrosomia. 
J Ultrasound Medicine. 2008;27:39–43.
64.  Uotila J, Dastidar P, Heinonen T, Rymin P, Punnonen R, Laasonen E. 
Magnetic resonance imaging compared to ultrasonography in fetal 
weight and volume estimation in diabetic and normal pregnancy. 
Acta Obstet Gynecol Scand. 2000;79:255–259.
65.  Lee W, Deter RL, Emersole JD, Huang R, Blanckaert K, Romero R: 
Birth weight prediction by three-dimensional ultrasonography: fractional 
limb volume. J Ultrasound Med. 2001;20:1283–1292.
66.  Meizner I, Mashiach R. Sonography in diabetic pregnancies. In: 
Hod M, Jovanovic L, Di Renzo GC, DeLeiva A, Langer O, eds. 
Textbook of Diabetes and Pregnancy. 2nd ed.Informa Healthcare; 2008; 
253–258.
67.  Schaefer-Graf UM, Kios SL, Fauzan OH, et al. A randomized trial 
evaluating a predominantly fetal growth-based strategy to guide 
management of gestational diabetes in Caucasian women. Diabetes 
Care. 2004;27:297–302.
68.  Bonomo M, Cetin I, Pisoni MP, et al. Flexible treatment of gesta-
tional diabetes modulated on ultrasound evaluation of intrauterine 
growth: a controlled randomized clinical trial. Diab Metab. 2004;30: 
237–243.
69.  Abramowicz JS, Sarosh R, Abramowicz S. Fetal cheek-to-cheek 
diameter in the prediction mode of delivery. Am J Obstet Gynaecol. 
2005;192:1205–1213.
70.  Bernstein IM, Catalano PM. Influence of foetal fat on the ultrasound 
estimation of foetal weight in diabetic mothers. Obstet Gynaecol. 
1992;79:561–563.
71.  Parretti E, Carignani I, Cioni R, et al. Sonographic evaluation of fetal 
growth and body composition in women with different degrees of 
normal glucose metabolism. Diabetes Care. 2003;26:2741–2748.
72.  Reader D, Splett P, Gunderson E. Impact of gestational diabetes mellitus 
nutrition practice guidelines implemented by registered dieticians on 
pregnancy outcome. J Am Diet Assoc. 2006;106:1426–1433.
73.  Food and Nutrition Board. Nutrition during pregnancy. Part 1:weight 
gain. Part 2: nutrient supplements. Washington DC: Institute of Medi-
cine, National Academy of Sciences; 1990.
74.  Knoop RH, Magee MS, Raisys V, Benetti T. Metabolic effects of 
hypocaloric diets in management of gestational diabetes. Diabetes. 
1991;40(Suppl 2):165–171.
75.  Magee MS, Knopp RH, Benedetti TJ. Metabolic effects of 1200 kcal 
diet in obese pregnant women with gestational diabetes. Diabetes. 
1990;34:234–240.
76.  Rizzo T, Metger BE, Burns WJ. Correlations between antepartum 
maternal metabolism and child intelligence. N Engl J Med. 1991;325: 
911–916.
77.  Rae A, Bond D, Evans S, North F, Robertman B, Walters B. 
A randomized controlled trial of dietary energy restriction in the 
management of obese women with gestational diabetes. Aust NZJ Obstet 
Gyn. 2000;40:416–422.
78.  Algert S, Shragg P, Hollingsworth DR. Moderate caloric restriction 
in obese women with gestational diabetes. Obstet Gynaecol. 1985;65: 
487–491.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 
is an international, peer-reviewed open-access journal committed 
to the rapid publication of the latest laboratory and clinical findings 
in the fields of diabetes, metabolic syndrome and obesity research.   
Original research, review, case reports, hypothesis formation, expert 
opinion and commentaries are all considered for publication. The 
manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
82
Lapolla et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
79.  Gillen l, Tapsell LC, Martin GS. The type and frequency of consumption 
of carbohydrate-rich foods may play a role in the clinical expression 
of insulin resistance during pregnancy. Nutrition and Dietetics. J Diet 
Assoc Australia. 2002;59(2):135–143.
80.  Nolan J. Improved glucose tolerance in gestational diabetic women 
on a low fat, high unrefined carbohydrate diet. Aust N Zel J Obstet 
Gynaecol. 1984;24(3):174–177.
81.  Ceysens G, Rouiller D, Boulvain M. Exercise for diabetic pregnant 
women. Cochrane Database Syst. Rev 3, CD004225(2006).
82.  Dyck R, Klomp H, Tan L, Turnell RW, Boctor MA. A comparison 
of rates, risk factors and outcomes of gestational diabetes between 
aboriginal and non aboriginal women in the Saskatoon health district. 
Diabetes Care. 2002;25:487–493.
83.  Dempsey J, Butler C, Sorensen TK, et al. A case-control study of 
maternal recreational physical activity and risk of gestational diabetes 
mellitus. Diab Res Clin Pract. 2004;66:203–215.
84.  American Diabetes Association. Medical management of pregnancy 
complicated by diabetes. ADA Clinical Education Series. 3rd ed. 
2000;126–128.
85.  Lapolla A, Dalfrà MG, Fedele D. Insulin therapy in pregnancy 
complicated by diabetes: are insulin analogs a new tool? Diabetes 
Metab Res Rev. 2005;21:241–252.
86.  Di Cianni G, Torlone E, Lencioni E, et al. Perinatal outcomes associ-
ated with the use of glargine during pregnancy. Diabet Med. 2008; 
25:993–996.
87.  Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. 
Transfer of insulin across the human placenta: in vitro perfusion studies. 
Diabetes Care. 2003;26(5):1390–1394.
88.  Jovanovic J, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of 
insulin lispro in gestational diabetes. Diabetes Care. 1999;22:1422–1427.
89.  Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety 
and lack of immunogenicity of insulin aspart compared with regular 
human insulin for women with gestational diabetes mellitus. Diabetic 
Medicine. 2007;24:1129–1135.
90.  Hofmann T, Horstmann G, Stammberger I. Evaluation of the 
reproductive toxicity and embryotoxicity of insulin glargine (Lantus) 
in rats and rabbits. Int J Toxicol. 2002;21(3):181–189.
91.  Price N, Bartlett G, Gillmer MD. Use of insulin glargine during 
pregnancy: a case-control pilot study. BJOG. 2007;114:453–457.
92.  Elliot BD, Langer O, Schenker S, Johnson RD, Prihoda T. Comparative 
placental transport of oral hypoglycemic agents in humans: a model 
of human placental drug transfer. Am J Obstet Gynaecol. 1994;171: 
653–660.
93.  Langer O, Yogev Y, Xenachis EMJ, Rosenn B. Insulin and glyburide 
therapy: dosage, severity level of gestational diabetes, and pregnancy 
outcome. Am J Obstet Gynaecol. 2005;192:134–139.
94.  Holt RI, Clarke P, Parry E C, Coleman MAG. The effectiveness of 
glibenclamide in women with gestational diabetes. Diabetes Obes 
Metab. 2008;10:906–911.
  95. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. 
Comparison of glyburide and insulin for the management of gestational 
diabetes in a large managed care organization. Am J Obstet Gynaecol. 
2005;193:118–124.
  96. Hague WM, Davoren PM, McIntyre D, Norris R, Xiaonian X, Charles B. 
Metformin crosses the placenta: a modulator for fetal insulin resistance? 
BMJ. 4 December 2003.
  97. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; for the MIG 
Trial Investigators. Metformin versus insulin for the treatment of 
gestational diabetes. N Engl J Med. 2008;358:2003–2015.
  98. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. 
Metformin therapy throughout pregnancy reduces the development of 
gestational diabetes in women with polycystic ovary syndrome. Fertil 
Steril. 2002;77(3):520–525.
  99. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, 
Wang P. Height, weight and motor-social development during the first 
18 months of life in 126 infants born to 109 mothers with polycystic 
ovary syndrome who conceived on and continued metformin through 
pregnancy. Hum Reprod. 2004;19(6):1323–1330.
100. de Veciana M,Trail PA, Lau TK, Dulaney K. A comparison of oral 
acarbose and insulin in women with gestational diabetes mellitus. 
Obstet Gynecol.2002;99:5S.
101. Chan LY,Yeung JH, Lau TK. Placental transfer of rosiglitazone in the 
first trimester of human pregnancy. Fert Steril 2005;83:955–958.
102. Hiles RA, Bawdon RE, Petrella EM. Ex vivo human placental 
transfer of the peptides pramlintide and exenatide. Hum Exp Toxicol. 
2003;22(12):623–628.